EUCTR2008-001355-21-IT进行中（未招募）不适用
First Line UFT, OXALIPLATIN and ERBITUX combination (TEGAFOX-E) in Elderly (= 70 years) metastatic colorectal patients: a Phase II ITMO study. - TEGAFOX-E
I.T.M.O. - ITALIAN TRIALS IN MEDICAL ONCOLOGY0 个研究点开始时间: 2008年12月18日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Elderly patients (≥ 70 years) with histologically documented metastatic adenocarcinoma of colon or rectum and the presence of at least one inidimensionally measurable lesion. Immunohistochemistry expression of EGFR on the primary tumor cells is not mandatory for patients` enrollement. Adjuvant chemotherapy, if administered, completed at least 6 months before study enrollment.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Serous illness or medical condition: congestive hearth failure or angina pectoris even medically controlled. Previous history of myocardial infarction within 1 year from study entry, uncontrolled high risk hypertension or arrythmya. Previous treatment for metastatic disease with chemotherapy and/or Erbitux. Presence of metastatic CNS involvement.
研究者
相似试验
进行中（未招募）
不适用
EOADJUVANT EPIRUBICIN-OXALIPLATIN-XELODA AND OXALIPLATIN-XELODA-RADIOTHERAPY IN LOCALLY ADVANCED, RESECTABLE, GASTRIC CANCER. A PHASE II COLLABORATIVE STUDY - NEOX-RT STUDYPATIENTS WITH OPERABLE GASTRIC ADENOCARCINOMAMedDRA version: 9.1Level: LLTClassification code 10061968Term: Gastric neoplasmEUCTR2008-002715-40-ITCENTRO DI RIFERIMENTO ONCOLOGICO DI AVIANO
进行中（未招募）
不适用
OPERA: OXALIPLATIN AND CETUXIMAB IN FIRST-LINE TREATMENT OF mCRCOpen, non-controlled, multicenter phase II study evaluating 5-FU/FA plus oxaliplatin (FOLFOX-4) plus cetuximab as first-line treatment for patients with undetectable EGFR-status in metastatic colorectal cancer. - OPERAEUCTR2005-005154-44-DEniversitätsklinikum Hamburg-Eppendorf70
进行中（未招募）
不适用
OPERA: OXALIPLATIN AND CETUXIMAB IN FIRST-LINE TREATMENT OF mCRCOpen, non-controlled, multicenter phase II study evaluating 5-FU/FA plus oxaliplatin (FOLFOX-4) plus cetuximab as first-line treatment for patients with undetectable EGFR-status in metastatic colorectal cancer. - OPERAmetastasized colorectal cancerEUCTR2005-005154-44-ATniversitätsklinikum Hamburg-Eppendorf72
已完成
2 期
Phase II Study of FOLFOX + Erbitux as first Line therapy in metastatic colorectal cancer with EGFR-detectable and KRAS wild typeMetastatic colorectal cancerJPRN-UMIN000004197Japan Clinical Cancer Research Organization54
进行中（未招募）
1 期
FLOX + Erbitux, 1a linjens-behandling till patienter med metastaserende kolorektalcancer och wild type K-RAS tumor - Nordic 7.5Patients with metastatic colorectal cancerMedDRA version: 9.1Level: LLTClassification code 10061451Term: Colorectal cancerEUCTR2007-007834-21-SEOdense University Hospital152